| First Author | Poulin EJ | Year | 2019 |
| Journal | Cancer Discov | Volume | 9 |
| Issue | 6 | Pages | 738-755 |
| PubMed ID | 30952657 | Mgi Jnum | J:276349 |
| Mgi Id | MGI:6314507 | Doi | 10.1158/2159-8290.CD-18-1220 |
| Citation | Poulin EJ, et al. (2019) Tissue-Specific Oncogenic Activity of KRAS(A146T). Cancer Discov 9(6):738-755 |
| abstractText | KRAS is the most frequently mutated oncogene. The incidence of specific KRAS alleles varies between cancers from different sites, but it is unclear whether allelic selection results from biological selection for specific mutant KRAS proteins. We used a cross-disciplinary approach to compare KRAS(G12D), a common mutant form, and KRAS(A146T), a mutant that occurs only in selected cancers. Biochemical and structural studies demonstrated that KRAS(A146T) exhibits a marked extension of switch 1 away from the protein body and nucleotide binding site, which activates KRAS by promoting a high rate of intrinsic and guanine nucleotide exchange factor-induced nucleotide exchange. Using mice genetically engineered to express either allele, we found that KRAS(G12D) and KRAS(A146T) exhibit distinct tissue-specific effects on homeostasis that mirror mutational frequencies in human cancers. These tissue-specific phenotypes result from allele-specific signaling properties, demonstrating that context-dependent variations in signaling downstream of different KRAS mutants drive the KRAS mutational pattern seen in cancer. SIGNIFICANCE: Although epidemiologic and clinical studies have suggested allele-specific behaviors for KRAS, experimental evidence for allele-specific biological properties is limited. We combined structural biology, mass spectrometry, and mouse modeling to demonstrate that the selection for specific KRAS mutants in human cancers from different tissues is due to their distinct signaling properties.See related commentary by Hobbs and Der, p. 696.This article is highlighted in the In This Issue feature, p. 681. |
